Novartis: launches patient trial for malaria drug.
(CercleFinance.com) - Novartis has launched with a non-profit organization a patient trial for a next-generation anti-malarial compound to treat drug-resistant strains of the disease.
The trial with Medicines for Malaria Venture (MMV) will test the efficacy of KAF156 in combination with a new, improved formulation of the existing anti-malarial lumefantrine.
A first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The trial with Medicines for Malaria Venture (MMV) will test the efficacy of KAF156 in combination with a new, improved formulation of the existing anti-malarial lumefantrine.
A first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.
Copyright (c) 2017 CercleFinance.com. All rights reserved.